Early Access — free while we kick the tires
EdgarHawk

Reitan Colleen F

Director

Director
3 filings analyzed · 2 companies · Latest 2025-09-11

Companies

Company Buys Sells Direction
ALNYLAM PHARMACEUTICALS, INC. ALNY 4 17 Net selling
MYRIAD GENETICS INC MYGN 0 1 Net selling

Activity

September 2025
high
Sell
18,000 shares
$8,416,730
Significance 7/10

Director Reitan sold 18,000 ALNY shares (95.9% of holdings) in 16 transactions for $8,416,729.64; stock now -2.8% from 52-week high.

Colleen F Reitan, a Director, executed 16 separate sales totaling 18,000 shares on 2025-09-09 at prices ranging from $457.44 to $476.31, with a blended average of $467.60, realizing $8,416,729.64 and reducing her holdings from 18.8K shares to 775 shares (a -95.9% reduction). The stock is currently at $468.58, only -2.8% from its 52-week high of $482.13, and has appreciated +9.0% over the last 30 days and +52.1% over 90 days. Her same-ticker history at ALNY shows mixed timing: a sell on 2025-04-16 that was poorly timed (stock rose +33.6% in the following 90 days), and two prior buys that declined -22.2% and -3.9% respectively. The company remains unprofitable (net income of -$66.3M in the latest quarter) despite strong revenue growth of +23.0% year-over-year, which may provide context for the scale and execution of this liquidation at near-peak valuations.

May 2025
Buy
36 shares
$10,363
Significance 4/10

Director Reitan bought 36 shares at avg $287.85, sold same 36 at $232.86 eight months later, crystallizing loss

Reitan Colleen F, a director, executed 2 purchases totaling 36 shares for $10,362.68 between August and October 2024, then sold all 36 shares on 2025-04-16 for $8,382.96, realizing a loss of approximately $1,980. The shares were sold at $232.86 per share, well below the average purchase price and below the 52-week high of $300.55, suggesting the director did not achieve favorable exit pricing. Across her open-market history at all tickers, the insider has a 100.00% well-timed selling rate, but this particular sale occurred while ALNY stock was still -10.1% from its 52-week high, indicating she exited before a potential recovery window. The company remains unprofitable (net income $-57,479,000.00 in the latest quarter) despite strong revenue growth of +23.0%, which may have motivated the liquidation of this small director position.

September 2024
2024-09-04 MYRIAD GENETICS INC MYGN
high
Sell
46,012 shares
$1,285,851
Significance 6/10

Director Colleen F Reitan sells 46,012 shares of MYGN at $27.95; cuts holdings by 52.0%

Director Colleen F Reitan sold 46,012 shares at $27.95 on 2024-09-03, reducing her position from 88,545 shares to 42,533 shares—a net reduction of 52.0% of pre-transaction holdings. The sale occurred near the 52-week high of $28.33, with the stock currently trading at $25.36, down 10.5% from that peak. The company is unprofitable, reporting net income of $-36,700,000.00 on revenue of $211,500,000.00 for the latest quarter, though annual revenue growth stands at 11.0%. The magnitude of this position reduction and its timing relative to recent price levels warrants examination of whether the director's confidence in the near-term outlook has shifted materially.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access